| pubmed-article:16338620 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16338620 | lifeskim:mentions | umls-concept:C0005961 | lld:lifeskim |
| pubmed-article:16338620 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:16338620 | lifeskim:mentions | umls-concept:C0301944 | lld:lifeskim |
| pubmed-article:16338620 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:16338620 | lifeskim:mentions | umls-concept:C0009647 | lld:lifeskim |
| pubmed-article:16338620 | lifeskim:mentions | umls-concept:C1332714 | lld:lifeskim |
| pubmed-article:16338620 | lifeskim:mentions | umls-concept:C1514562 | lld:lifeskim |
| pubmed-article:16338620 | lifeskim:mentions | umls-concept:C1883221 | lld:lifeskim |
| pubmed-article:16338620 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:16338620 | lifeskim:mentions | umls-concept:C1883204 | lld:lifeskim |
| pubmed-article:16338620 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:16338620 | lifeskim:mentions | umls-concept:C1880389 | lld:lifeskim |
| pubmed-article:16338620 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:16338620 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:16338620 | pubmed:dateCreated | 2005-12-12 | lld:pubmed |
| pubmed-article:16338620 | pubmed:abstractText | Host CD4(+) T cells that survive sublethal or even lethal preconditioning regimens can participate in the process of hematopoietic stem cell graft rejection, particularly when the transplantations are performed across a major histocompatibility complex (MHC) class II barrier. To enhance donor marrow engraftment, we tested the efficacy of a small synthetic cyclic heptapeptide, 802-2 (CNSNQIC), which was designed to closely mimic the CD4 domain 1 CC' surface loop, theoretically involved in CD4/MHC class II complex oligomerization and subsequent CD4(+) T-cell activation. Previously, this peptide was found to have inhibitory activity in murine models for CD4(+) T cell-dependent graft-versus-host disease and skin allograft rejection. Herein, we used the MHC class II--disparate bm12 --> B6-CD45.1 sublethal irradiation transplantation model to test the possibility that the 802-2 peptide could enhance the engraftment of donor T cell-depleted bone marrow (ATBM). Sublethally irradiated B6-CD45.1 mice that received bm12 ATBM in combination with the 802-2 peptide demonstrated increased donor marrow cell engraftment as compared with mice that received ATBM alone; this suggests that the 802-2 peptide may be useful as an immunomodulating agent to overcome MHC class II mismatch barriers in hematopoietic stem cell transplantation. | lld:pubmed |
| pubmed-article:16338620 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16338620 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16338620 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16338620 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16338620 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16338620 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16338620 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16338620 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16338620 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:16338620 | pubmed:issn | 1083-8791 | lld:pubmed |
| pubmed-article:16338620 | pubmed:author | pubmed-author:KorngoldRober... | lld:pubmed |
| pubmed-article:16338620 | pubmed:author | pubmed-author:FriedmanThea... | lld:pubmed |
| pubmed-article:16338620 | pubmed:author | pubmed-author:VaradiGaborG | lld:pubmed |
| pubmed-article:16338620 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16338620 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:16338620 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16338620 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16338620 | pubmed:pagination | 979-87 | lld:pubmed |
| pubmed-article:16338620 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:16338620 | pubmed:meshHeading | pubmed-meshheading:16338620... | lld:pubmed |
| pubmed-article:16338620 | pubmed:meshHeading | pubmed-meshheading:16338620... | lld:pubmed |
| pubmed-article:16338620 | pubmed:meshHeading | pubmed-meshheading:16338620... | lld:pubmed |
| pubmed-article:16338620 | pubmed:meshHeading | pubmed-meshheading:16338620... | lld:pubmed |
| pubmed-article:16338620 | pubmed:meshHeading | pubmed-meshheading:16338620... | lld:pubmed |
| pubmed-article:16338620 | pubmed:meshHeading | pubmed-meshheading:16338620... | lld:pubmed |
| pubmed-article:16338620 | pubmed:meshHeading | pubmed-meshheading:16338620... | lld:pubmed |
| pubmed-article:16338620 | pubmed:meshHeading | pubmed-meshheading:16338620... | lld:pubmed |
| pubmed-article:16338620 | pubmed:meshHeading | pubmed-meshheading:16338620... | lld:pubmed |
| pubmed-article:16338620 | pubmed:meshHeading | pubmed-meshheading:16338620... | lld:pubmed |
| pubmed-article:16338620 | pubmed:meshHeading | pubmed-meshheading:16338620... | lld:pubmed |
| pubmed-article:16338620 | pubmed:meshHeading | pubmed-meshheading:16338620... | lld:pubmed |
| pubmed-article:16338620 | pubmed:meshHeading | pubmed-meshheading:16338620... | lld:pubmed |
| pubmed-article:16338620 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16338620 | pubmed:articleTitle | A CD4 domain 1 CC' loop peptide analogue enhances engraftment in a murine model of bone marrow transplantation with sublethal conditioning. | lld:pubmed |
| pubmed-article:16338620 | pubmed:affiliation | Kimmel Cancer Center, Jefferson Medical College, Philadelphia, Pennsylvania, USA. | lld:pubmed |
| pubmed-article:16338620 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16338620 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
